mTOR Co-Targeting in Cetuximab Resistance in Head and Neck Cancers Harboring PIK3CA and RAS Mutations

Reverse-Phase Protein Array Profiling of Oropharyngeal Cancer and Significance of PIK3CA Mutations in HPV-Associated Head and Neck Cancer

(2014) A. Sewell et al.   CLINICAL CANCER RESEARCH

Anti-lymphangiogenic properties of mTOR inhibitors in head and neck squamous cell carcinoma experimental models

(2013) Oleksandr Ekshyyan et al.   BMC CANCER

Cetuximab-Activated Natural Killer and Dendritic Cells Collaborate to Trigger Tumor Antigen-Specific T-cell Immunity in Head and Neck Cancer Patients

(2013) R. M. Srivastava et al.   CLINICAL CANCER RESEARCH

A role for p38 MAPK in head and neck cancer cell growth and tumor-induced angiogenesis and lymphangiogenesis

(2013) Kantima Leelahavanichkul et al.   Molecular Oncology

Exploiting the Head and Neck Cancer Oncogenome: Widespread PI3K-mTOR Pathway Alterations and Novel Molecular Targets

(2013) R. Iglesias-Bartolome et al.   Cancer Discovery

Frequent Mutation of the PI3K Pathway in Head and Neck Cancer Defines Predictive Biomarkers

(2013) V. W. Y. Lui et al.   Cancer Discovery

Integrative Genomic Characterization of Oral Squamous Cell Carcinoma Identifies Frequent Somatic Drivers

(2013) C. R. Pickering et al.   Cancer Discovery

High Frequency of Activating PIK3CA Mutations in Human Papillomavirus–Positive Oropharyngeal CancerPIK3CA in HPV+ Oropharyngeal Squamous Cell Carcinoma

(2013) Anthony C. Nichols   JAMA Otolaryngology-Head & Neck Surgery

Metformin Prevents the Development of Oral Squamous Cell Carcinomas from Carcinogen-Induced Premalignant Lesions

(2012) L. Vitale-Cross et al.   Cancer Prevention Research

mTOR Signaling in Growth Control and Disease

(2012) Mathieu Laplante et al.   CELL

mTOR as a Molecular Target in HPV-Associated Oral and Cervical Squamous Carcinomas

(2012) A. A. Molinolo et al.   CLINICAL CANCER RESEARCH

mTOR Inhibitors and its Role in the Treatment of Head and Neck Squamous Cell Carcinoma

(2012) Shaun A. Nguyen et al.   CURRENT TREATMENT OPTIONS IN ONCOLOGY

Molecular phenotype predicts sensitivity of squamous cell carcinoma of the head and neck to epidermal growth factor receptor inhibition

(2012) Natalie R. Young et al.   Molecular Oncology

Identification of a mutation in the extracellular domain of the Epidermal Growth Factor Receptor conferring cetuximab resistance in colorectal cancer

(2012) Clara Montagut et al.   NATURE MEDICINE

Decreased Lymphangiogenesis and Lymph Node Metastasis by mTOR Inhibition in Head and Neck Cancer

(2011) V. Patel et al.   CANCER RESEARCH

AMPK and mTOR regulate autophagy through direct phosphorylation of Ulk1

(2011) Joungmok Kim et al.   NATURE CELL BIOLOGY

Mutational analysis of PTEN/PIK3CA/AKT pathway in oral squamous cell carcinoma

(2011) Yoram Cohen et al.   ORAL ONCOLOGY

Activation of ERBB2 Signaling Causes Resistance to the EGFR-Directed Therapeutic Antibody Cetuximab

(2011) K. Yonesaka et al.   Science Translational Medicine

The Epidermal Growth Factor Receptor Antibody Cetuximab Induces Autophagy in Cancer Cells by Downregulating HIF-1  and Bcl-2 and Activating the Beclin 1/hVps34 Complex

(2010) X. Li et al.   CANCER RESEARCH

Investigational EGFR-targeted therapy in head and neck squamous cell carcinoma

(2010) Andre Cassell et al.   EXPERT OPINION ON INVESTIGATIONAL DRUGS

EGFR–PI3K–AKT–mTOR signaling in head and neck squamous cell carcinomas: attractive targets for molecular-oriented therapy

(2010) Christian Freudlsperger et al.   EXPERT OPINION ON THERAPEUTIC TARGETS

Molecular Mechanisms of Resistance to Cetuximab and Panitumumab in Colorectal Cancer

(2010) Alberto Bardelli et al.   JOURNAL OF CLINICAL ONCOLOGY

Understanding resistance to EGFR inhibitors—impact on future treatment strategies

(2010) Deric L. Wheeler et al.   Nature Reviews Clinical Oncology

Targeting Mammalian Target of Rapamycin by Rapamycin Prevents Tumor Progression in an Oral-Specific Chemical Carcinogenesis Model

(2009) R. Czerninski et al.   Cancer Prevention Research

Chemical Carcinogenesis Models for Evaluating Molecular-Targeted Prevention and Treatment of Oral Cancer

(2009) L. Vitale-Cross et al.   Cancer Prevention Research

Rapamycin Prevents Early Onset of Tumorigenesis in an Oral-Specific K-ras and p53 Two-Hit Carcinogenesis Model

(2009) A. R. Raimondi et al.   CANCER RESEARCH

Establishment and Characterization of a Model of Acquired Resistance to Epidermal Growth Factor Receptor Targeting Agents in Human Cancer Cells

(2009) S. Benavente et al.   CLINICAL CANCER RESEARCH

Radiotherapy plus cetuximab for locoregionally advanced head and neck cancer: 5-year survival data from a phase 3 randomised trial, and relation between cetuximab-induced rash and survival

(2009) James A Bonner et al.   LANCET ONCOLOGY

Implications for KRAS status and EGFR-targeted therapies in metastatic CRC

(2009) Nicola Normanno et al.   Nature Reviews Clinical Oncology

Nuclear EGFR contributes to acquired resistance to cetuximab

(2009) C Li et al.   ONCOGENE

A Retroinhibition Approach Reveals a Tumor Cell-Autonomous Response to Rapamycin in Head and Neck Cancer

(2008) P. Amornphimoltham et al.   CANCER RESEARCH

Emerging perspectives in epidermal growth factor receptor targeting in head and neck cancer

(2008) Seungwon Kim et al.   HEAD AND NECK-JOURNAL FOR THE SCIENCES AND SPECIALTIES OF THE HEAD AND NECK

Platinum-Based Chemotherapy plus Cetuximab in Head and Neck Cancer

(2008) Jan B. Vermorken et al.   NEW ENGLAND JOURNAL OF MEDICINE

Mechanisms of acquired resistance to cetuximab: role of HER (ErbB) family members

(2008) D L Wheeler et al.   ONCOGENE

Antitumor Activity of Rapamycin in a Phase I Trial for Patients with Recurrent PTEN-Deficient Glioblastoma

(2008) Tim F Cloughesy et al.   PLOS MEDICINE